Transcriptome analysis reveals the effect of oral contraceptive use on cervical cancer

Gao,Tian; Wang,Jianjun; Yang,Min; Li,Huaifang

doi:10.3892/mmr.2014.2466

Transcriptome analysis reveals the effect of oral contraceptive use on cervical cancer

Authors:
- Tian Gao
- Jianjun Wang
- Min Yang
- Huaifang Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji University, Shanghai 200065, P.R. China, Department of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou 310006, P.R. China
Published online on: August 8, 2014 https://doi.org/10.3892/mmr.2014.2466
Pages: 1703-1708
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Differentially‑expressed genes (DEGs) correlated to oral contraceptives (OCs) were identified by comparing the transcriptomes of cervical cancer patients who have taken OCs and those who have not. Their biological functions and relevance to clinical manifestations were investigated further in order to gain an understanding of the pathogenesis of cervical cancer and provide potential therapeutic targets. Level 3 RNA‑sequencing (seq) data for cervical squamous‑cell carcinoma and endocervical adenocarcinoma and the clinical information were downloaded from The Cancer Genome Atlas. The present study analyzed the RNA‑seq data and information on OC use of 35 patients [OC users (n=18) and those who have never used OCs (n=17)]. Student's t‑test was used in order to identify DEGs and the false discovery rate (FDR) was estimated by a Beta‑Uniform Mixture model, which was adopted in multiple testing corrections. A functional enrichment analysis was performed with the Database for Annotation, Visualization and Integrated Discovery tool and BioCarta. A total of 80 DEGs were identified in OC users while FDR=0.3 was set as the cut‑off value. The metabolic process and human telomerase RNA gene transcription were significantly upregulated in DEGs. Furthermore, secreted LY6/PLAUR domain containing 1 was identified to be correlated to the pathological response, while the synapse defective 1 Rho GTPase homolog 2 was found to be significantly associated with the histological grade and overall survival time. In conclusion, present study shed light on the effect of OC use on the oncogenesis of the cervix and may indicate novel approaches for a targeted therapy of cervical cancer.

View Figures

View References

1	Brake T and Lambert PF: Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA. 102:2490–2495. 2005. View Article : Google Scholar
2	Kjellberg L, Hallmans G, Hren A, et al: Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 82:13322000.PubMed/NCBI
3	Ness RB, Grisso JA, Klapper J, et al: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 152:233–241. 2000. View Article : Google Scholar : PubMed/NCBI
4	Smith JS, Green J, De Gonzalez AB, et al: Cervical cancer and use of hormonal contraceptives: a systematic review. The Lancet. 361:1159–1167. 2003. View Article : Google Scholar : PubMed/NCBI
5	Sasieni P: Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Commentary Lancet. 370:2007.
6	Moodley M, Moodley J, Chetty R and Herrington C: The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer. 13:103–110. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rivera R, Yacobson I and Grimes D: The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 181:1263–1269. 1999. View Article : Google Scholar : PubMed/NCBI
8	Guven S, Kart C, Guvendag Guven ES and Serdar Gunalp G: The underlying cause of cervical cancer in oral contraceptive users may be related to cervical mucus changes. Med Hypotheses. 69:550–552. 2007. View Article : Google Scholar
9	The R Development Core Team. R: A language and environment for statistical computing. http://www.R-project.org. Accessed March 26, 2013
10	Pounds S and Morris SW: Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics. 19:1236–1242. 2003. View Article : Google Scholar
11	Da Wei Huang BTS and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2008.PubMed/NCBI
12	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 289–300. 1995.
13	Godsland IF, Crook D, Simpson R, et al: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 323:1375–1381. 1990. View Article : Google Scholar
14	Krauss RM and Burkman R Jr: The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 167:11771992. View Article : Google Scholar : PubMed/NCBI
15	Petrenko A, Pavlova L, Karseladze A, Kisseljov F and Kisseljova N: Downregulation of genes encoding for subunits of adaptor complex-3 in cervical carcinomas. Biochemistry (Moscow). 71:1153–1160. 2006. View Article : Google Scholar : PubMed/NCBI
16	Odorizzi G, Cowles CR and Emr SD: The AP-3 complex: a coat of many colours. Trends Cell Biol. 8:282–288. 1998. View Article : Google Scholar : PubMed/NCBI
17	Honig A, Weidler C, Häusler S, et al: Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res. 30:1559–1564. 2010.PubMed/NCBI
18	Gavrilescu MM, Todosi AM, Anitei MG, Filip B and Scripcariu V: Expression of bmi-1 protein in cervical, breast and ovarian cancer. Rev Med Chir Soc Med Nat Iasi. 116:1112–1117. 2012.PubMed/NCBI
19	Guilleret I, Yan P, Guillou L, Braunschweig R, Coindre J-M and Benhattar J: The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis. 23:2025–2030. 2002. View Article : Google Scholar : PubMed/NCBI
20	Cairney C and Keith W: Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie. 90:13–23. 2008. View Article : Google Scholar : PubMed/NCBI
21	Guo Q, Sui L and Feng Y: Cervical cancer screening: hTERC gene amplification detection by FISH in comparison with conventional methods. Open Journal of Obstetrics and Gynecology. 2:11–17. 2012. View Article : Google Scholar
22	Zhao JQ, Glasspool RM, Hoare SF, et al: Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia. 2:531–539. 2000. View Article : Google Scholar : PubMed/NCBI
23	Pettersson A, Nordlander S, Nylund G, et al: Expression of the endogenous, nicotinic acetylcholine receptor ligand, SLURP-1, in human colon cancer. Auton Autacoid Pharmacol. 28:109–116. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kalantari-Dehaghi M, Bernard HU and Grando SA: Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells. Life Sci. 91:1122–1125. 2012. View Article : Google Scholar : PubMed/NCBI
25	Iorns E, Ward TM, Dean S, et al: Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat. 135:79–91. 2012. View Article : Google Scholar : PubMed/NCBI
26	Hill VK, Ricketts C, Bieche I, et al: Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 71:2988–2999. 2011. View Article : Google Scholar